Your browser doesn't support javascript.
loading
Safety and Efficacy of Eucaloric Very Low-Carb Diet (EVLCD) in Type 1 Diabetes: A One-Year Real-Life Retrospective Experience.
Kleiner, Andrea; Cum, Barbara; Pisciotta, Livia; Cincione, Ivan Raffaele; Cogorno, Ludovica; Prigione, Amalia; Tramacere, Antonio; Vignati, Andrea; Carmisciano, Luca; Sukkar, Samir Giuseppe.
Afiliação
  • Kleiner A; Salus AlpeAdria Diabetes Center, 33100 Udine, Italy.
  • Cum B; Salus AlpeAdria Diabetes Center, 33100 Udine, Italy.
  • Pisciotta L; Dietetics and Clinical Nutrition Unit, IRCCS Policlinic Hospital San Martino, 16132 Genoa, Italy.
  • Cincione IR; Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
  • Cogorno L; Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
  • Prigione A; Dietetics and Clinical Nutrition Unit, IRCCS Policlinic Hospital San Martino, 16132 Genoa, Italy.
  • Tramacere A; Department of Experimental Medicine-Medical Pathophysiology, Food Science and Endocrinology Section, Sapienza University of Rome, 00185 Rome, Italy.
  • Vignati A; Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
  • Carmisciano L; Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
  • Sukkar SG; Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
Nutrients ; 14(15)2022 Aug 05.
Article em En | MEDLINE | ID: mdl-35956384
ABSTRACT
A eucaloric very low carbohydrate diet (EVLCD) is a diet with a daily caloric intake equal to the total daily energy expenditure (TDEE) with a carbohydrate content of <50 g/day. The literature on very low carbohydrate diets (VLCD) in type 1 diabetes (DM 1) is limited, although recently published scientific studies have highlighted their safety and efficacy in managing DM 1. In this retrospective analysis, we report the clinical data of 33 patients affected by DM 1 carrying out insulin therapy who switched voluntarily from their usual diet (high carb, low fat) to an EVLCD. Our aim is to evaluate the glycemic control, the amount of insulin needed in order to maintain glycemic control and safety of EVLCD. The switch improved glycemic control (mean glycated hemoglobin decreased from 8.3% to 6.8% (p < 0.01). The number of patients who reached a glycated hemoglobin value of <7% increased statistically from 12% to 57% (p < 0.01), and there was a statistically significant decrease (p < 0.01) in the units of daily insulin (from 36.7± 14.9 IU to 28.9 ±9.1 IU) A reduction from 54% to 24% in clinical level 2 hypoglycemia episodes was reported. No cases of severe hypoglycemia or ketoacidosis were observed. The results of the study support that EVLCD in DM 1 seems safe and effective when adopted under tight medical supervision.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Hipoglicemia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Hipoglicemia Idioma: En Ano de publicação: 2022 Tipo de documento: Article